Non-small Cell Lung Cancer

CLINICAL_TRIALS research · 2025-05-23

Clinical Trial Update: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing [Phase 2]

NeoTRACK is a Phase 2 trial evaluating immuno-oncology efficacy in non-small cell lung cancer; the study is currently active but not recruit…

CLINICAL_TRIALS research · 2025-05-23

Clinical Trial Update: PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC [Phase 2]

The PROPHET study is a Phase 2 clinical trial evaluating ctDNA-guided personalized induction immunochemotherapy for non-small cell lung canc…

CLINICAL_TRIALS research · 2025-05-23

Clinical Trial Update: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer [Phase 3]

This is a Phase 3 trial evaluating osimertinib with or without chemotherapy versus chemotherapy alone as neoadjuvant therapy for patients wi…

CLINICAL_TRIALS other · 2025-05-23

Clinical Trial Update: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification [Phase 3]

Phase 3 trial update on Savolitinib in combination with Osimertinib for advanced non-small cell lung cancer with MET amplification; the stud…

CLINICAL_TRIALS research · 2025-05-22

Clinical Trial Update: Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

This clinical trial update describes a Shanghai Chest Hospital study analyzing the molecular landscape of non-small cell lung cancer patient…

CLINICAL_TRIALS research · 2025-05-22

Clinical Trial Update: Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

This clinical trial analyzes resistance to immune checkpoint inhibitors in non-small cell lung cancer. It is currently recruiting.

CLINICAL_TRIALS trial_result · 2025-05-21

Clinical Trial Update: Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations [Phase 1]

A Phase 1 trial is evaluating the combination of pembrolizumab and trametinib for patients with stage IV non-small cell lung cancer, includi…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. [Phase 2]

Phase 2 trial evaluating first-line Vebreltinib plus PLB1004 in patients with EGFR-mutant, MET-positive locally advanced or metastatic Non-S…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI [Phase 1, Phase 2]

This Clinical Trial Update describes a Phase 1/2 study of Vebreltinib plus PLB1004 in EGFR-mutated, advanced non-small cell lung cancer with…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure [Phase 3]

Phase 3 trial evaluating Vebreltinib plus PLB1004 versus platinum-based doublet chemotherapy in EGFR-mutant, MET-positive non-small cell lun…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. [Phase 2]

Phase 2 clinical trial evaluating limertinib plus bevacizumab versus limertinib as first-line treatment for EGFR-mutant, PD-L1 positive adva…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer [Phase 2]

This entry covers the National Lung Matrix Trial, a multi-drug Phase II study in non-small cell lung cancer, with the trial currently active…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

A clinical trial is recruiting to evaluate how bone metastases in non-small cell lung cancer with actionable driver mutations respond to tyr…

CLINICAL_TRIALS research · 2025-05-20

Clinical Trial Update: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) [Phase 1, Phase 2]

KL264-01, a Trop2-targeted antibody-drug conjugate, is being studied in a Phase 1/2 trial for advanced unresectable or metastatic solid tumo…

CLINICAL_TRIALS trial_result · 2025-05-20

Clinical Trial Update: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China [Phase 1]

The Phase 1 study of JAB-3312 in adults with advanced solid tumors in China has completed.

CLINICAL_TRIALS research · 2025-05-20

Clinical Trial Update: Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy [EARLY_Phase 1]

It announces an early-phase trial exploring whether circulating tumor DNA can guide postoperative radiation therapy decisions in non-small c…

CLINICAL_TRIALS research · 2025-05-20

Clinical Trial Update: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) [Phase 1]

This clinical trial update reports an ongoing Phase 1 study evaluating datopotamab deruxtecan in combination with pembrolizumab, with or wit…

CLINICAL_TRIALS trial_result · 2025-05-18

Clinical Trial Update: TGRX-326 Pharmacokinetic Food Effect Bioavailability Study [Phase 1]

Phase 1 pharmacokinetic study evaluating the impact of food on the bioavailability of a drug in development for non-small cell lung cancer; …